Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nightingale Health

1.88 EUR-1.32 %16.11. klo 13.36
4,828 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Short Selling
Investor views
Compare
-1.32 %
+63.76 %
+118.02 %
+89.78 %
-8.54 %
-23.78 %
+59.44 %
-44.85 %
-63.59 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
114.26M EUR
Turnover
39.66K EUR
P/E (adj.) (27e)
EV/EBIT (adj.) (27e)
P/B (27e)
EV/S (27e)
Dividend yield-% (27e)
Coverage
Recommendation
Accumulate
Target price
Updated
03.11.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Inderes Nightingale Healthin sairastumisriskien tunnistus saataville Alankomaissa... Nightingale Health Oyj | Lehdistötiedote | 10.11.2026 klo 09:00:00 EETNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) ja VitaHealth BV ovat sopineet Nightingale Remote Health......
11/10/2026, 7:03 AM
by Pertti
21
Inderes Nightingale Healthin sairastumisriskien tunnistus osaksi lontoolaisen Barnes... Nightingale Health Oyj | Lehdistötiedote | 06.11.2026 klo 11:00:00 EETNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), sairastumisriskien tunnistamisen ja ennaltaehkäisevän.....
11/6/2026, 9:02 AM
by Pertti
17
Now! Inderes Nightingale Health etenee Yhdysvalloissa: New Yorkin osavaltio hyväksyi... Nightingale Health Oyj | Lehdistötiedote | 05.11.2026 klo 09:45:00 EETNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), sairastumisriskien tunnistamisen ja ennaltaehkäisevän.....
11/5/2026, 7:50 AM
by Pertti
15
mtvuutiset.fi – 11 Nov 26 Työttömien terveystarkastuksiin uusi verikoe: Sairastumisriskejä arvioidaan... Työttömien terveystarkastuksissa otetaan käyttöön verikokeeseen perustuva elintapasairauksien riskiarvio.
11/11/2026, 9:39 AM
by Pertti
13
Well, well. It could be that these continuous little breadcrumbs of news are (no longer so weak) signals of an impending tsunami. And these have been dropping for the third year now. Hopefully, the perfectly timed documentary about Elizabeth Holmes (Theranos) will add even more grist...
11/6/2026, 9:50 AM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
9
There was just a segment of a few minutes on this on the 10 o’clock news! Nightingale wasn’t mentioned by name, but it’s great if this helps generate more interest and buzz around it
11/11/2026, 8:17 PM
by Yariskuski
7
It is important to note that, according to the release, approval has currently only been granted for certain individual blood biomarkers. According to the company’s website, the measurement currently includes around 250+ blood biomarkers, so we will still have to wait before the ...
11/5/2026, 8:13 AM
by Satunnaisotanta
4
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 03.11.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
9.3.
2027

Interim report Q2'27

Press release10.11.2026 klo 09.00

Nightingale Health's disease risk detection becomes available in the Netherlands through VitaHealth

Nightingale Health
Press release06.11.2026 klo 11.00

Nightingale Health's disease risk detection becomes part of annual health assessments at Barnes Private Practice in London

Nightingale Health
Regulatory press release05.11.2026 klo 17.25

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release05.11.2026 klo 09.45

Nightingale Health reaches next milestone in the United States: first laboratory developed tests approved by New York State

Nightingale Health
Press release04.11.2026 klo 09.00

Nightingale Health's disease risk detection becomes part of a longevity membership at S-Thetics Clinic in the United Kingdom

Nightingale Health
Nightingale: Contracts keep flowing
Research03.11.2026 klo 10.04
by Antti Siltanen, Antti Luiro

Nightingale: Contracts keep flowing

The company has received 3 proteomics orders in a short space of time.

Nightingale Health
Press release02.11.2026 klo 15.00

Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

Nightingale Health
Nightingale’s deal flow keeps a healthy beat
Analyst Comment29.10.2026 klo 09.05
by Antti Siltanen

Nightingale’s deal flow keeps a healthy beat

The new contracts put upward pressure on our forecasts for the current financial year.

Nightingale Health
Regulatory press release28.10.2026 klo 21.15

Inside information: Nightingale Health signs USD 1 million proteomics agreement with Alzheimer's Research UK, for neurodegenerative disease research

Nightingale Health
Regulatory press release28.10.2026 klo 16.35

Inside information: Nightingale Health signs USD 1 million proteomics agreement with LifeArc, for neurodegenerative disease research

Nightingale Health
Analyst Comment23.10.2026 klo 08.56
by Antti Siltanen

Nightingale's tests added to health assessments offered by British The Private GP Group

The new contract integrates blood analyses as part of health assessments.

Nightingale Health
Press release22.10.2026 klo 09.30

Nightingale Health's disease risk detection becomes part of annual health assessments at The Private GP Group in the United Kingdom

Nightingale Health
Nightingale: Growth boost from proteomics
Research08.10.2026 klo 10.01
by Antti Siltanen, Antti Luiro

Nightingale: Growth boost from proteomics

The protein analysis project will generate significant growth for the current fiscal year.

Nightingale Health
Nightingale's tests integrated into Siun sote's health checks
Analyst Comment06.10.2026 klo 09.11
by Antti Siltanen

Nightingale's tests integrated into Siun sote's health checks

North Karelia is adopting risk tests as part of statutory health checks.

Nightingale Health
Press release05.10.2026 klo 10.10

Nightingale Health's disease risk detection becomes part of health checks for the unemployed in the Wellbeing Services County of North Karelia in Finland

Nightingale Health
Regulatory press release01.10.2026 klo 17.15

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health
Nightingale secures a major 5.8 MEUR project with the Michael J. Fox Foundation
Analyst Comment02.10.2026 klo 10.30
by Antti Luiro

Nightingale secures a major 5.8 MEUR project with the Michael J. Fox Foundation

To the best of our knowledge, this is the company’s most valuable commercial contract to date and demonstrates once again the company’s ability to carry out large-scale research projects.

Nightingale Health
Regulatory press release01.10.2026 klo 08.30

Nightingale Health’s Annual Report for financial year 2025–2026 has been published

Nightingale Health
Regulatory press release30.09.2026 klo 20.09

Inside information: Nightingale Health signs USD 6.5 million proteomics agreement with the Michael J. Fox Foundation for neurodegenerative disease research

Nightingale Health
Press release29.09.2026 klo 09.00

Nightingale Health's disease risk detection becomes available in Latvia through Professor Skride's Heart Clinic

Nightingale Health